Genotropin Pen 12mg (36IU) Pfizer
Genotropin Pen HGH (human Growth Hormone) – 36 IU (12 mg) is used for human growth hormone replacement therapy. It is a synthetic 191 amino acid sequence identical to human growth hormone that is naturally produced in the body by the pituitary gland. Human growth hormone can affect the use of carbohydrates and fat in the cells. Boost verifies lean mass and decreasing fat human value hormone (HGH).
Genotropin Pen is an injectable drug representing a synthetic Human Growth Hormone produced with recombinant DNA technology. It is also called Somatotropin and refers to the growth hormone produced natively in animals. Among athletes and bodybuilders it is used to gain extra muscles and to burn the unnecessary fat in the human body. It also increases the energy levels, improves the skin texture and immune system functions. Genotropin helps the body to recover between workouts and posses the ability to increase calcium retention and to strengthen the mineralization of bones.
Treatment with Genotropin Pen Pfizer for short stature should be discontinued when the epiphyses are fused.
Pediatric Growth Hormone Deficiency (GHD)
- Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended.
- Generally, a dose of 0.24 mg/kg body weight/week is recommended.
- Generally, a dose of 0.33 mg/kg body weight/week is recommended.
Idiopathic Short Stature
- Generally, a dose up to 0.47 mg/kg body weight/week is recommended.
Small for Gestational Age1
- Generally, a dose of up to 0.48 mg/kg body weight/week is recommended.
Dosing of Adult Patients :
Adult Growth Hormone Deficiency (GHD)
Either of two approaches to Genotropin Pen dosing may be followed: a non-weight based regimen or a weight based regimen.
Non-weight based — based on published consensus guidelines, a starting dose of approximately 0.2 mg/day (range, 0.15–0.30 mg/day) may be used without consideration of body weight. This dose can be increased gradually every 1–2 months by increments of approximately 0.1–0.2 mg/day, according to individual patient requirements based on the clinical response and serum insulin-like growth factor I (IGF-I) concentrations. The dose should be decreased as necessary on the basis of adverse events and/or serum IGF-I concentrations above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person, and between male and female patients.
Weight based — based on the dosing regimen used in the original adult GHD registration trials, the recommended dosage at the start of treatment is not more than 0.04 mg/kg/week. The dose may be increased according to individual patient requirements to not more than 0.08 mg/kg/week at 4 to 8 week intervals. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-I concentrations should be used as guidance in dose titration.
– Tunnel syndrome
– Inhibition of thyroid function
– Fluid retention
– Increased blood pressure